Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial

被引：5
|
作者：
Cheung, Chee Kay [1 ,2 ]
Barratt, Jonathan [1 ,2 ]
机构：
[1] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England
[2] Univ Hosp Leicester NHS Trust, John Walls Renal Unit, Leicester, Leics, England
来源：
KIDNEY INTERNATIONAL | 2020年 / 98卷 / 04期
关键词：
D O I：
10.1016/j.kint.2020.05.033
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The role of immunosuppression in the management of IgA nephropathy remains highly controversial. The Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) trial suggested that there was no benefit with the addition of immunosuppression to intensive supportive care, in terms of renal outcome. In this edition of Kidney International, Rauen et al. report long-term outcomes from the STOP-IgAN trial. Crown Copyright (C) 2020, Published by Elsevier, Inc., on behalf of the International Society of Nephrology. All rights reserved.
引用
下载
收藏
页码：836 / 838
页数：4
相关论文
共 50 条
  • [11] PHENYTOIN IN IGA NEPHROPATHY - A LONG-TERM CONTROLLED TRIAL
    EGIDO, J
    RIVERA, F
    SANCHO, J
    BARAT, A
    HERNANDO, L
    NEPHRON, 1984, 38 (01) : 30 - 39
  • [12] Long-term Trastuzumab treatment: can we ever stop?
    Keane, F.
    Walsh, E.
    Sui, J.
    Marks, S.
    O'leary, C.
    Gleeson, J.
    Keane, M.
    O'Reilly, S.
    BREAST, 2017, 32 : S66 - S66
  • [13] Long-Term Outcomes of Patients with IgA Nephropathy Categorized by the International IgAN Risk Prediction Tool and by the Degree of Hematuria at Diagnosis
    Ebbestad, Robin
    Sanaei Nurmi, Mazdak
    Lundberg, Sigrid
    NEPHRON, 2022, 146 (06) : 573 - 583
  • [14] Should We Stop Calling Thanatophoric Dysplasia a Lethal Condition? A Case Report of a Long-Term Survivor
    Carroll, Ricki S.
    Duker, Angela L.
    Schelhaas, Andrea J.
    Little, Mary Ellen
    Miller, Elissa G.
    Bober, Michael B.
    PALLIATIVE MEDICINE REPORTS, 2020, 1 (01): : 32 - 39
  • [15] Long-term treatment with fish oil reduces renal progression in patients with IgA nephropathy (IgAN).
    Donadio, JV
    Dart, RA
    Grande, JP
    Bergstralh, EJ
    Spencer, DC
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A0406 - A0406
  • [16] MODELLING LONG-TERM OUTCOMES FOR PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN) FROM SHORT-TERM PROTEINURIA DATA
    Bensink, Mark
    Sullivan, Sean
    Zhou, Jenny
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I25 - I26
  • [17] LONG-TERM OUTCOMES OF ALISKIREN ADDED TO LOSARTAN IN IGA NEPHROPATHY
    Lie, Davina Ngoi Wah
    Chan, Gary C. W.
    Tang, Sydney C. W.
    Lai, K. N.
    NEPHROLOGY, 2020, 25 : 35 - 35
  • [18] Long-Term Outcomes of IgA Nephropathy Presenting with Minimal or No Proteinuria
    Gutierrez, Eduardo
    Zamora, Isabel
    Antonio Ballarin, Jose
    Arce, Yolanda
    Jimenez, Sara
    Quereda, Carlos
    Olea, Teresa
    Martinez-Ara, Jorge
    Segarra, Alfons
    Bernis, Carmen
    Garcia, Asuncion
    Goicoechea, Marian
    Garcia de Vinuesa, Soledad
    Rojas-Rivera, Jorge
    Praga, Manuel
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (10): : 1753 - 1760
  • [19] Long-term outcomes of the Stop Traumatic OASI Morbidity Project (STOMP)
    Basu, Maya
    Smith, Dot
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2018, 142 (03) : 295 - 299
  • [20] Long-Term Results of a Randomized Controlled Trial in Childhood IgA Nephropathy
    Kamei, Koichi
    Nakanishi, Koichi
    Ito, Shuichi
    Saito, Mari
    Sako, Mayumi
    Ishikura, Kenji
    Hataya, Hiroshi
    Honda, Masataka
    Iijima, Kazumoto
    Yoshikawa, Norishige
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (06): : 1301 - 1307
12345